1 er therapeutic (n=59) or subtherapeutic (59) nCPAP (about 1 cm H(2)O pressure) for 1 month.

2 tcomes were not found between the HHHFNC and nCPAP/BiPAP groups, including duration of respiratory su

3   In patients with most severe sleep apnoea, nCPAP reduces blood pressure, providing significant vasc

4  positive airway pressure (nCPAP) or bilevel nCPAP (BiPAP) as a primary approach to RDS in infants ol

5 l or placebo treatment, the mean duration of nCPAP use was 6.2 h/night, with no significant change fr

6 owed efficacy and safety similar to those of nCPAP/BiPAP when applied as a primary approach to mild t

7 mization to either HHHFNC at 4 to 6 L/min or nCPAP/BiPAP at 4 to 6 cm H2O.

8 o nasal continuous positive airway pressure (nCPAP) or bilevel nCPAP (BiPAP) as a primary approach to

9 y nasal continuous positive airway pressure (nCPAP), such treatment could reduce risk of cardiovascul

10 t robust control intervention subtherapeutic nCPAP.

11 y 2.5 mm Hg (SE 0.8), whereas subtherapeutic nCPAP increased blood pressure by 0.8 mm Hg (0.7) (diffe

12 .1 [1.9] weeks; 52.5% female) and 158 in the nCPAP/BiPAP group (mean [SD] GA, 33.0 [2.1] weeks; 47.5%

13                                  Therapeutic nCPAP reduced mean arterial ambulatory blood pressure by

14         The use of HHHFNC was noninferior to nCPAP with regard to the primary outcome: failure occurr

15                   Our aim was to see whether nCPAP for sleep apnoea reduces blood pressure compared w